Abstract Data unveiled at this year’s ASCO Annual meeting show that GRAIL’s Galleri multi-cancer early detection (MCED) test failed to reduce stage III and IV cancers in the landmark NHS-Galleri trial, although there was an improvement in stage IV alone. Experts say the findings fall short of demonstrating a large enough clinical benefit for MCED testing that would warrant Galleri’s implementation.
A Sat, study studied this question.